Every 8-K that VICARIOUS SRGCL INC A (RBOT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RBOT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RBOT filings page.
Vicarious Surgical, Inc. approved a general assignment for the benefit of creditors, transferring all or substantially all assets to Vicarious Liquidation, LLC. Under this structure, creditors are expected to have priority over stockholders for distributions, and stockholders are not expected to receive any distribution unless assets remain after satisfying all liabilities.
Stockholders at a Special Meeting approved an assignment for the benefit of creditors followed by a voluntary dissolution and liquidation. The board then determined the dissolution was in the company’s best interests and approved a Plan of Dissolution, under which a Certificate of Dissolution will be filed with the Delaware Secretary of State on or about July 22, 2026.
The board decided to voluntarily terminate registration of the common stock and intends to file Form 15, which will immediately suspend obligations to file Forms 10-K, 10-Q and 8-K and is expected to become effective 90 days after filing. All directors have submitted resignations effective upon the Form 15 filing, and the CEO, President, CTO and Chief Medical Officer were terminated on July 21, 2026, with contractual cash severance of $672,699, $779,190 and $611,261 respectively and full vesting of their time-based equity awards, subject to treatment under the assignment and applicable law.
Vicarious Surgical Inc. reported that Chief Financial Officer Sarah Romano has resigned. She notified the Board on June 24, 2026, with her resignation effective July 22, 2026, or a later mutually agreed date. The company states her resignation is not due to any disagreement regarding operations, policies, or practices. Ms. Romano will continue to serve as CFO until her resignation becomes effective.
Vicarious Surgical Inc. held a special stockholder meeting where investors approved an amendment to its Certificate of Incorporation to enable a reverse stock split of its Class A and Class B common stock at a ratio between 1-for-2 and 1-for-30, with the exact ratio to be set by the Board.
Stockholders representing 1,885,434 shares, or about 60.68% of the total voting power, were present, satisfying quorum requirements. The reverse stock split proposal passed with 11,810,046 votes for, 49,675 against, and 3,430 abstentions, indicating strong support for giving the Board flexibility to adjust the share count and price structure.
Vicarious Surgical Inc. reported continued operating losses and confirmed that its common stock has been delisted from the New York Stock Exchange and is now quoted on the OTCID market.
For 2025, the company posted a net loss of $50.2 million, lower than the $63.2 million net loss in 2024. Total operating expenses fell to $50.0 million from $66.6 million, reflecting reduced research and development and general and administrative spending.
Liquidity weakened materially: cash and cash equivalents were $2.6 million and short-term investments $7.2 million at December 31, 2025, down from $9.7 million and $39.4 million a year earlier. Total assets declined to $19.6 million and stockholders’ equity to $9.8 million, from $67.7 million and $46.7 million respectively.
The NYSE delisted the shares after the company’s average global market capitalization over 30 trading days fell below $15 million. The company chose not to appeal, obtained OTCID quotation on March 4, 2026 under the symbol RBOT, and has applied to upgrade to the OTCQB market, with no assurance on future trading liquidity.
Vicarious Surgical Inc. reported changes to executive compensation for two senior leaders. On March 4, 2026, the company entered into amendments to the Executive Employment Agreements for Adam Sachs, its President, and Sammy Khalifa, its Chief Technology Officer.
Under these amendments, Mr. Sachs agreed to voluntarily reduce his annual base salary to approximately $270,810, and Mr. Khalifa agreed to reduce his annual base salary to approximately $318,600. Despite these reductions, any target bonus amounts and severance payments under their employment agreements will continue to be calculated using the higher base salaries that were in effect immediately before these amendments. The amendments are filed as Exhibits 10.1 and 10.2.
Vicarious Surgical Inc. reports that the New York Stock Exchange has suspended trading in its common stock and begun proceedings to delist it. The NYSE determined the company no longer meets the continued listing requirement for an average global market capitalization of at least $15,000,000 over 30 trading days.
The company has received approval to have its shares quoted on the OTCID market operated by OTC Markets, and expects trading there to begin on March 4, 2026 under the symbol RBOT. Management notes that OTC quotation is a significantly more limited and less liquid market, which may reduce trading activity, pressure the share price, hinder equity fundraising, limit access to public capital markets, and weaken the company’s ability to offer equity incentives to employees.
Vicarious Surgical Inc. filed an 8-K describing updated severance and change in control protections for its Chief Executive Officer and Chief Financial Officer. CEO Stephen From received an amendment to his employment agreement that provides severance if he is terminated without cause or resigns for good reason, including enhanced cash payments, continued COBRA health premiums and full vesting of time-based equity if the termination occurs in connection with a change in control.
CFO Sarah Romano entered into a new Executive Severance and Change in Control Agreement with similar protections, scaled to her role. Her agreement also offers higher severance multiples, extended COBRA coverage and full vesting of time-based equity awards if a qualifying termination occurs within a defined window around a change in control. Both arrangements require signing a separation agreement with a release and restrictive covenants.
Vicarious Surgical Inc. reported the results of a special stockholder meeting held on January 9, 2026. Stockholders voted on a single proposal related to warrants previously issued by the company.
Holders of Class A and Class B common stock, voting together as a single class, approved the exercise of warrants issued on October 7, 2025 to purchase up to an aggregate of 2,300,000 shares of Class A common stock. The proposal passed with 14,991,093 votes in favor, 23,052 votes against, and 2,894 abstentions.
There were 2,591,229 shares of Class A and Class B common stock present or represented by proxy at the meeting, representing approximately 78.18% of the outstanding total voting power entitled to vote, which was sufficient to constitute a quorum.
Vicarious Surgical Inc. entered into an at-the-market offering agreement with H.C. Wainwright & Co., allowing the company to sell shares of its Class A common stock from time to time through the sales agent, subject to a new Form S-3 shelf registration statement becoming effective. The ATM prospectus supplement currently permits sales of shares with an aggregate market value of $2,286,052, based on the limitations of General Instruction I.B.6 of Form S-3.
The company will pay Wainwright a 3.0% commission on gross proceeds, plus specified fees and expenses, and can set parameters such as timing, daily limits, and minimum prices for any share sales. Separately, the NYSE has begun proceedings to delist and has immediately suspended trading in Vicarious Surgical’s publicly traded warrants (symbol “RBOT.WS”) due to “abnormally low” trading price levels, and the company does not intend to appeal. The Class A common stock will continue trading on the NYSE under “RBOT,” but its continued listing depends on regaining compliance with NYSE Section 802.01B by October 10, 2026. The company also issued a press release announcing guidance for anticipated cash burn for fiscal year 2026.
Vicarious Surgical Inc. reported governance changes as two directors, Beverly Huss and Randy Clark, resigned from its Board of Directors effective December 1, 2025. The company stated their resignations were part of a Board decision to reduce its size and were not due to any disagreement over operations, policies, or practices.
Following these departures, the Board was reduced from nine members to seven. To fill committee roles, Joseph Doherty joined the Audit Committee, Fuad Ahmad joined the Compensation Committee, and Victoria Carr‑Brendel was named Chair of the Compensation Committee, all effective the same day.
On December 3, 2025, Vicarious Surgical also announced via press release that it had updated guidance on its 2025 cash burn and highlighted the committee changes. This press release was furnished as an exhibit and not deemed filed for liability purposes under securities laws.
Vicarious Surgical Inc. furnished an 8‑K announcing its results for the third quarter ended September 30, 2025, along with a business update. The company provided the details via a press release furnished as Exhibit 99.1.
The company noted that the information in this report, including Exhibit 99.1, is being furnished and is not deemed filed under Section 18 of the Exchange Act or incorporated by reference unless expressly stated.
Vicarious Surgical Inc. entered into a securities purchase agreement for a capital raise using a registered direct offering and a concurrent private placement. The company will sell 588,300 shares of Class A common stock and pre-funded warrants to purchase up to 561,700 additional shares, together with Series A and Series B common warrants to purchase a total of 2,300,000 shares, all at an exercise price of $5.10 per share for the common warrants. Vicarious Surgical expects to receive approximately $5.9 million in gross proceeds before fees and expenses.
The pre-funded warrants are immediately exercisable at $0.0001 per share and are subject to a 9.99% beneficial ownership cap. The common warrants become exercisable after stockholder approval and include ownership limits of 4.99% or, at the holder’s election, 9.99%, as well as adjustment and fundamental transaction protections. The company agreed to short-term restrictions on issuing additional equity and on variable rate transactions, and its officers and directors will be subject to a 30-day lock-up.
Vicarious Surgical Inc. reported a leadership change on its board of directors. On September 25, 2025, the board appointed Joseph Doherty to serve as Chairman of the Board. He joined the board earlier in the year following his election at the annual meeting of stockholders held on June 27, 2025.
Doherty already serves as a member of the board’s Compensation Committee and as Chairman of the Nominating and Corporate Governance Committee, indicating an active role in executive pay decisions and board oversight. The company also issued a press release announcing his appointment, which is furnished as an exhibit but is not considered filed for liability purposes under securities laws.
Vicarious Surgical, Inc. filed a Form 8-K reporting a material event that attaches an Investor Presentation as Exhibit 99.1 and includes the interactive cover page XBRL file. The filing lists trading symbols for the company’s common stock and warrants on the New York Stock Exchange, including warrants to purchase one share of Class A common stock at an exercise price of $11.50 per share (symbol RBOT WS). The document is signed by Stephen From, Chief Executive Officer. The filing text supplied is brief and contains exhibit and header details without additional financial tables, transaction terms, or earnings information.
Vicarious Surgical Inc. filed an 8-K reporting a material event dated September 12, 2025. The filing lists corporate identifiers and contact details and shows trading symbols RBOT and RBOT WS on the New York Stock Exchange. It discloses warrants exercisable to purchase one share of Class A common stock at an exercise price of $11.50 per share. The form is signed by Stephen From, Chief Executive Officer. The filing contains limited narrative or financial detail beyond the warrant description and administrative information.
Vicarious Surgical Inc. filed a current report to let investors know it has updated its investor presentation as of September 8, 2025. Senior management plans to use this updated presentation in meetings with investors and analysts, including at the H.C. Wainwright 27th Annual Global Investment Conference in New York, where Chief Executive Officer Stephen From is scheduled to present at approximately 9:00 a.m. Eastern Time on September 10, 2025.
The updated investor presentation is available on the company’s investor relations website and is also furnished as Exhibit 99.1 to this report. The company notes that the presentation is furnished, not filed, which means it is not subject to certain liability provisions of the Securities Exchange Act and is not automatically incorporated into other securities filings unless specifically referenced.
Vicarious Surgical Inc. furnished a Current Report announcing that it issued a press release with its results for the second quarter ended June 30, 2025 and providing a business update. The 8-K attaches that press release as Exhibit 99.1 and includes an Inline XBRL cover page file as Exhibit 104. The filing states the furnished materials are not "filed" for purposes of the Exchange Act and are not incorporated by reference elsewhere unless explicitly stated. The report does not include financial tables, numerical earnings or balance sheet figures within the filing itself; readers must consult the attached press release for detailed results.
Vicarious Surgical Inc. (NYSE: RBOT) filed an 8-K covering governance and compensation actions taken at its 27 June 2025 Annual Meeting.
Equity Incentive Plan: Shareholders approved an amendment to the 2021 Equity Incentive Plan that raises the share reserve by 311,046 Class A common shares. The same incremental amount is now available specifically for Incentive Stock Options. All other plan terms remain unchanged and the full amended text is included as Exhibit 10.1.
Director Compensation Policy: Effective the same date, the Board adopted a restated non-employee director compensation policy. Key features include:
- Creation of a new Product & Technology Committee with annual cash retainers of $14,250 for the chair and $5,500 for members.
- Updated annual cash retainers across all committees (e.g., Audit Committee member — $6,300; Board member base retainer — $40,000).
- Flexibility for the Compensation Committee to grant equity awards at values below stated guidelines.
- Initial equity awards to new directors valued at up to $301,800 and annual awards valued at up to $145,000, delivered as RSUs or options.
Annual Meeting Voting: Approximately 4.1 million shares (≈90 % of voting power) were present, constituting a quorum. All nine director nominees were re-elected with more than 97 % of votes cast "for" each nominee. The equity plan amendment passed with 14,678,240 votes "for" (≈99.6 %), 50,817 "against" and 3,907 abstentions. Broker non-votes totaled 1,788,342.
No other material transactions, earnings data or strategic changes were disclosed.